)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Amneal Pharmaceuticals
Amneal Pharmaceuticals (AMRX) investor relations material
Amneal Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary14 Jan, 2026
Strategic vision and transformation
Aims to become the top affordable medicines provider in the U.S. by 2030, focusing on access, availability, support, and innovation, with 98% of revenue from the domestic market and selective global expansion through partnerships.
Mission is to expand access to high-quality, innovative medicines for all patients, improving standards of care and delivering value to the healthcare system.
Transformation is 70-75% complete for complex generics, with biosimilars integration as the next five-year focus and a diversified portfolio across generics, injectables, biosimilars, and specialty branded products.
R&D investment is shifting from complex generics to biosimilars and branded specialty, with over 50% of future spend allocated to these areas.
Financial discipline remains a priority, with net leverage targeted below 3x and strong cash flow supporting growth.
Portfolio expansion and product innovation
Portfolio includes 280+ affordable medicines, with a record number of complex generic therapy approvals and 20-30 key product launches annually.
Specialty branded products such as CREXONT® for Parkinson's and Brekiya® for migraine drive high-value growth, with CREXONT® expected to reach $120M+ in sales this year and projected peak sales of $300M-$500M.
Six biosimilars expected by 2027, with a pipeline including Denosumab (Prolia/Xgeva), Xolair, and others, supported by dual BLAs and global supply strategies.
New branded products include an FDA-approved DHE auto-injector for migraines and cluster headaches, offering at-home treatment.
Ophthalmic, inhalation, and depot products are key growth drivers, with recent approvals paving the way for future launches.
Financial performance and growth outlook
Net revenues projected at $3.0–$3.1B for 2025, up from $1.6B in 2019, with adjusted EBITDA expected to reach $675M–$685M and operating cash flow of $300M–$330M.
Net leverage reduced from 7.4x in 2019 to 3.7x in 2025, with a revenue CAGR of 11% and adjusted EBITDA CAGR of 13% from 2019 to 2024.
Affordable medicines segment expected to double in the next few years, driven by biosimilars and complex injectables.
High single-digit growth projected for generics and AvKare government channel, with specialty and biosimilars as major contributors.
EBITDA and EPS are set to grow faster than revenue, with 20-25%+ EPS growth expected due to refinancing and operational efficiencies.
Non-oral solid revenue contribution
GLP-1 manufacturing facility completion timeline
Denosumab biosimilar launch timing
How will biosimilar vertical integration impact leverage?
CREXONT market share trajectory and peak sales?
R&D spend allocation shift by segment
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Amneal Pharmaceuticals earnings date
Q4 20256 Mar, 2026
Amneal Pharmaceuticals
Next Amneal Pharmaceuticals earnings date
Q4 20256 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Amneal Pharmaceuticals, Inc. is a pharmaceutical company engaged in the development, manufacturing, and distribution of generic and specialty pharmaceutical products. The company offers a wide range of dosage forms, including oral solids, injectables, and topicals, addressing therapeutic areas such as central nervous system disorders, oncology, and cardiovascular conditions. The company is headquartered in Bridgewater, New Jersey, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage